GlassScriptPhysician profile
William J Martin
NPI 1215115639
$4,836.23
in general payments reported to CMS, 2019-2025
29 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $766 · 2021: $714 · 2022: $603 · 2023: $752 · 2024: $703 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,694.77 | 2020-2025 | |
| Glaxosmithkline, LLC. | $422.94 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $400.71 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Janssen Pharmaceuticals, INC | $392.78 | 2020-2022 | |
| Pfizer INC. | $331.25 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $237.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $219.87 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $160.11 | 2019-2024 | Linzess |
| Amgen INC. | $150.24 | 2020-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $142.43 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $94.53 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.68 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $62.15 | 2021-2022 | |
| Corcept Therapeutics | $58.71 | 2020-2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $57.11 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $54.42 | 2023-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $49.30 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $44.76 | 2020-2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $26.41 | 2020-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $24.53 | 2020-2023 | Livalo, Seglentis |
| Vapotherm INC | $22.36 | 2022 | |
| Amarin Pharma, INC. | $21.95 | 2021 | |
| Optinose US, INC. | $20.13 | 2020 | |
| Lilly USA, LLC | $14.95 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.54 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.79 | 2019 | |
| Hikma Pharmaceuticals USA | $12.65 | 2019 | |
| Abbott Laboratories | $12.50 | 2019 | |
| Kaleo, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.